Medical device companies' aggregate spend on payment and other gifts to physicians was at least $200 million last year, according to the U.S. Health & Human Services Dept., but critics (and the agency itself) flag widespread problems with the Open Payments database.
InfoBionic closes the 2nd tranche of its $17 million Series B financing, attracting interest from Excel Venture Management and a Blue Cross Blue Shield subsidiary.
An investment subsidiary of Blue Cross Blue Shield of Massachusetts signed on for the 2nd tranche of InfoBionic's $17 million Series B financing. The Lowell, Mass.-based startup plans to use the cash infusion to commercialize its cloud-based remote patient monitoring system in the U.S. and Europe.
Vector is Children's Hospital Boston's blog about research and innovation in pediatric and adult medicine. We report and comment on medical innovations and advances – from bench to bedside – touching on scientific, business and policy issues. Our ranks include science writers, physicians, lab researchers, market analysts and others inside and outside the hospital.
Short snippets of DNA called aptamers (red) readily get into cancer cells (green and blue) on their own (left panel). They can't penetrate cells when stuck to an oligonucleotide (center), but regain the ability when the oligonucleotide's bonds are broken by UV light (right). (Images courtesy Lele Li, PhD.)
The Emergo Group Blog provides short updates on quality and regulatory topics that may be of interest to QA/RA professionals in the medical device and IVD industry. No fluff, just straight to the point. We hope you'll enjoy the content.
Medical device regulators in the US have extended their Unique Device Identification compliance deadline to September 24, 2016 for some implantable medical devices to provide more time for manufacturers of these devices to develop and implement workable UDI processes.
In order to qualify for the extension, a device must meet three key criteria: